AIThe Next Webabout 2 hours ago
MindRank's oral GLP-1 reaches Phase III on $23M
1 min read
MindRank's MDR-001, an oral small-molecule GLP-1 receptor agonist, reached Phase III trials in about 4.5 years on roughly $23 million of research spending. The Hangzhou company closed a $52M Series B in July and runs the Molecule Arts AI platform. Clinical data remains unpublished.
Level
Hype check
Tap to vote and see what everyone thinks.
